Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: Results from the ARBI prospective clinical trial

Abstract

Purpose: We investigated whether age at anastrozole (A) initiation influences the effect of treatment on bone mineral density (BMD). We conducted a post hoc analysis of the dataset of Arimidex Bone Mass Index Oral Bis-phosphonates prospective trial, studying the effect of risedronate (R) on BMD of postmenopausal, early breast cancer patients receiving A. Methods: Patients were stratified into those with normal BMD or mild osteopenia (T>-2) receiving A-only and patients with mild or severe osteopenia (T ≤ -2) or osteoporosis (T